Shire's Elvanse/Vyvanse no better than Lilly's Strattera for ADHD, says Germany
This article was originally published in Scrip
Executive Summary
There is no proof that Shire's Elvanse/Vyvanse (lisdexamfetamine dimesylate) offers any additional benefit compared to Lilly's Strattera (atomoxetine) for treating attention deficit hyperactivity disorder, says IQWiG, which carries out the preliminary scientific assessment under Germany's tough new AMNOG pricing and reimbursement system.